Marginal zone lymphoma patient study
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at patients with marginal zone lymphoma who were diagnosed and treated at a specific hospital in Italy between 2012 and 2018. It aims to learn more about how the disease progresses and how patients respond to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with marginal zone lymphoma between December 2012 and December 2018.
- You were treated at the IRCCS Azienda Ospedaliero-Universitaria di Bologna hospital.
- You are 18 years old or older.
- You can give written permission to be in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how well and how safely zanubrutinib worked for people with marginal zone lymphoma who got the drug through a special access program in Italy. The goal is to learn more about the drug's real-world effects and help future patients.
This study is for adults newly diagnosed with lymphoma in the last 3 months, including those who may have started treatment. It aims to collect information on patients in Italy.
This is a study that looks back and forward at people diagnosed with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or a related early condition called MBL. It aims to improve how these conditions are recognized and managed over time in Italy.
This study aims to understand how common skin lymphomas are in Italy. You might be able to help if you have been diagnosed with a skin lymphoma.
This study looks at the cells and genetics of MALT lymphoma, a type of slow-growing lymphoma. It aims to learn more about the disease and may help find better ways to treat it.
This study is for people who were just diagnosed with marginal zone lymphoma (a slow-growing blood cancer) and haven't started treatment yet. Researchers will collect blood and tissue samples and follow you over time to learn more about the disease.
Hear when a new Marginal Zone B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.